Abstract
BackgroundTo date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. However, treatment failures are common and the occurrence of severe toxicities, such...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have